Aspirin has limited ability to modulate shear-mediated platelet activation associated with elevated shear stress of ventricular assist devices

被引:27
作者
Valerio, Lorenzo [1 ,5 ]
Tran, Phat L. [2 ]
Sheriff, Jawaad
Brengle, William [2 ]
Ghosh, Ram
Chiu, Wei-Che
Redaelli, Alberto [1 ]
Fiore, Gianfranco B. [1 ]
Pappalardo, Federico
Bluestein, Danny [4 ]
Slepian, Marvin J. [2 ,3 ,4 ]
机构
[1] Politecn Milan, Dept Elect Informat & Bioengn, I-20133 Milan, Italy
[2] Univ Arizona, Dept Biomed Engn, Tucson, AZ USA
[3] Univ Arizona, Dept Med, Sarver Heart Ctr, 1501 North Campbell Ave, Tucson, AZ 85721 USA
[4] SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA
[5] Ist Sci San Raffaele, Dept Cardiothorac Anesthesia & Intens Care, Milan, Italy
关键词
Aspirin; Thrombosis; Platelets; Shear; Ventricular assist devices; Mechanical circulatory support; MECHANICAL CIRCULATORY SUPPORT; THROMBUS FORMATION; HEART-FAILURE; WHOLE-BLOOD; IN-VITRO; FLOW; AGGREGATION; DIPYRIDAMOLE; PREVENTION; RESISTANCE;
D O I
10.1016/j.thromres.2016.01.026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Continuous flow ventricular assist devices (cfVADs) while effective in advanced heart failure, remain plagued by thrombosis related to abnormal flows and elevated shear stress. To limit cfVAD thrombosis, patients utilize complex anti-thrombotic regimens built upon a foundation of aspirin (ASA). While much data exists on ASA as a modulator of biochemically-mediated platelet activation, limited data exists as to the efficacy of ASA as a means of limiting shear-mediated platelet activation, particularly under elevated shear stress common within cfVADs. We investigated the ability of ASA (20, 25 and 125 mu M) to limit shear-mediated platelet activation under conditions of: 1) constant shear stress (30 dynes/cm(2) and 70 dynes/cm(2)); 2) dynamic shear stress, and 3) initial high shear exposure (70 dynes/cm(2)) followed by low shear exposure -i.e. a platelet sensitization protocol, utilizing a hemodynamic shearing device providing uniform shear stress in vitro. The efficacy of ASA to limit platelet activation mediated via passage through a clinical cfVAD system (DeBakey Micromed) in vitro was also studied. ASA reduced platelet activation only under conditions of low shear stress (38% reduction compared to control, n = 10, p < 0.004), with minimal protection at higher shear stress and under dynamic conditions (n = 10, p > 0.5) with no limitation of platelet sensitization. ASA had limited ability (25.6% reduction in platelet activation rate) to modulate shear-mediated platelet activation induced via cfVAD passage. These findings, while performed under "deconstructed" non-clinical conditions by utilizing purified platelets alone in vitro, provide a potential contributory mechanistic explanation for the persistent thrombosis rates experienced clinically in cfVAD patients despite ASA therapy. An opportunity exists to develop enhanced pharmacologic strategies to limit shear-mediated platelet activation at elevated shear levels associated with mechanical circulatory support devices. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:110 / 117
页数:8
相关论文
共 50 条
[1]  
AARTS PAMM, 1984, BLOOD, V64, P1228
[2]   Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack [J].
Adams, Robert J. ;
Albers, Greg ;
Alberts, Mark J. ;
Benavente, Oscar ;
Furie, Karen ;
Goldstein, Larry B. ;
Gorelick, Philip ;
Halperin, Jonathan ;
Harbaugh, Robert ;
Johnston, S. Claiborne ;
Katzan, Irene ;
Kelly-Hayes, Margaret ;
Kenton, Edgar J. ;
Marks, Michael ;
Sacco, Ralph L. ;
Schwamm, Lee H. .
STROKE, 2008, 39 (05) :1647-1652
[3]   Design Optimization of a Mechanical Heart Valve for Reducing Valve Thrombogenicity-A Case Study with ATS Valve [J].
Alemu, Yared ;
Girdhar, Gaurav ;
Xenos, Michalis ;
Sheriff, Jawaad ;
Jesty, Jolyon ;
Einav, Shmuel ;
Bluestein, Danny .
ASAIO JOURNAL, 2010, 56 (05) :389-396
[4]  
Barstad RM, 1996, THROMB HAEMOSTASIS, V75, P827
[5]   INHIBITION OF PLATELET PROSTAGLANDIN SYNTHETASE BY ORAL ASPIRIN [J].
BURCH, JW ;
STANFORD, N ;
MAJERUS, PW .
JOURNAL OF CLINICAL INVESTIGATION, 1978, 61 (02) :314-319
[6]   Aspirin and clopidogrel - Efficacy, safety, and the issue of drug resistance [J].
Cattaneo, M .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (11) :1980-1987
[7]   Thromboresistance Comparison of the HeartMate II Ventricular Assist Device With the Device Thrombogenicity Emulation-Optimized HeartAssist 5 VAD [J].
Chiu, Wei-Che ;
Girdhar, Gaurav ;
Xenos, Michalis ;
Alemu, Yared ;
Soares, Joao S. ;
Einav, Shmuel ;
Slepian, Marvin ;
Bluestein, Danny .
JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME, 2014, 136 (02)
[8]   Thrombogenic Potential of Innovia Polymer Valves versus Carpentier-Edwards Perimount Magna Aortic Bioprosthetic Valves [J].
Claiborne, Thomas E. ;
Girdhar, Gaurav ;
Gallocher-Lowe, Siobhain ;
Sheriff, Jawaad ;
Kato, Yasushi P. ;
Pinchuk, Leonard ;
Schoephoerster, Richard T. ;
Jesty, Jolyon ;
Bluestein, Danny .
ASAIO JOURNAL, 2011, 57 (01) :26-31
[9]   Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination [J].
Cooke, GE ;
Liu-Stratton, YW ;
Ferketich, AK ;
Moeschberger, ML ;
Frid, DJ ;
Magorien, RD ;
Bray, PF ;
Binkley, PF ;
Goldschmidt-Clermont, PJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (03) :541-546
[10]  
CRAVEN L L, 1950, J Insur Med, V5, P47